SEC Form 4 · accession 0001209191-17-009269
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Paul Baker
Officer — SVP, Development Sciences
Period of report
Feb 7, 2017
Accepted (ET)
Feb 9, 2017 · 7:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 7, 2017 | A | 5,625 | $0.00 | A | 88,389 | D | |
| Common StockF3 | Feb 7, 2017 | A | 7,031 | $0.00 | A | 95,420 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $45.38 | Feb 7, 2017 | A | 25,000 | A | — | Feb 6, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 5, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.
- F2Includes 264 shares of common stock granted to the reporting person by Five Prime Therapeutics, Inc. pursuant to a company match under Five Prime Therapeutics, Inc.'s 401(k) plan.
- F3Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on February 5, 2019 and two-thirds (2/3) of the restricted stock will vest on February 5, 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.
- F4The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month beginning on March 7, 2017, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.